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Continuous ambulatory peritoneal dialysis and survival of HIV infected
patients with end-stage renal disease. As the number of human immuno-
deficiency virus (HIV) infected patients has increased in the U.S., the
number of infected patients treated for end-stage renal disease (ESRD)
has stabilized at about I to 2% of the hemodialyzed population. Little
has been written regarding the role of continuous ambulatory peritoneal
dialysis (CAPD) in the treatment of HIV infected patients with ESRD.
To evaluate the effectiveness of CAPD as a long term therapy for HIV
infected patients with ESRD, we reviewed our ESRD program's
experience. We entered 392 patients from its inception in February 1984
until April 1992. Thirty-one, or 7.9% of our population were HIV
infected. Twenty, or 64.5% had stage IV infection. Patients were
entered into our chronic hemodialysis (HD) or CAPD program accord-
ing to standard clinical criteria. Eight HIV infected patients elected to
start CAPD, while 23 patients were treated exclusively with HD. The
proportion of stage IV infected patients was similar in both treatment
modality groups. HIV infected ESRD patients were younger than
non-HJV infected patients (37.5 9.7 vs. 49.8 15.7 years, respec-
tively, P < 0.0001) at the start of treatment. We used Cox regression
techniques to analyze survival data. Mean survival time for our entire
non-HIV infected ESRD population (N = 361) was 44.0 33.9months.
Mean survival time for HIV infected patients with ESRD was 15.5 9.9
months. Median survival for HIV infected ESRD patients was 13
months compared to 38 months for the non-infected population. As
expected, mean survival time in HIV infected ESRD patients was
significantly diminished compared to non-infected ESRD patients (P <
0.0001). When HIV infected patients were analyzed separately, how-
ever, there was no difference in mean survival time between patients
treated with HD and CAPD (14.7 9.7 vs. 17.9 10.7 months,
respectively). Age, HIV status and stage of HIV infection were
predictors of survival in ESRD patients, while sex and race were not.
The peritonitis rate in HIV infected patients treated with CAPD was not
different from that in non-HIV infected CAPD patients. The etiologic
agents of peritonitis in the HIV-infected population were similar to
those in non-infected populations. We conclude that HD and CAPD are
equally good treatment alternatives for HIV infected patients with
ESRD.
Human immunodeficiency virus (HIV)-associated nephropa-
thy (HIVAN) has become a more frequent reason for admission
to end-stage renal disease (ESRD) programs. The prevalence of
HIV infected patients in hemodialysis (HD) units has ap-
proached Ito 2% of the population [1—3], although much higher
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prevalences have been reported in selected inner-city dialysis
units in Miami, New York City and Washington, D.C. [4—61.
HD has been recognized as accepted therapy for HIV infected
patients with ESRD [7].
Little has been written regarding the role of continuous
ambulatory peritoneal dialysis (CAPD) in the treatment of HIV
infected patients with ESRD [8]. The prevalence of HIV
infection in the ESRD population treated with CAPD has not
been studied extensively, but at least one report suggests that it
might be substantial [9]. Theoretically such treatment might
interfere with protein metabolism, and result in diminished
survival. In addition a few reports of peritonitis in selected
patients treated with both acute and chronic peritoneal dialysis
have emerged [8, 10—16].
In order to evaluate the effectiveness of CAPD as a long-term
therapy for HIV infected patients with ESRD, we reviewed our
experience in the ESRD program at the George Washington
University Medical Center.
Methods
Three hundred and ninety-two patients with ESRD were
treated at the George Washington University Hospital and
Medical Center from the inception of our unit in February 1984
to April 1992. The demographic characteristics of our patients
are outlined in Table 1. Patients were entered into chronic HD
or CAPD programs according to clinical criteria and mutual
decision by attending staff and patients.
All ESRD patients in our program were screened for HIV
infection by ELISA in October 1985. Thereafter, HIV serology
was tested in patients with risk factors for the development of
AIDS, and/or clinical evidence of immunosuppression or HIV-
related illness. In addition, after the availability of HIV sero-
logic surveillance, patients with renal insufficiency and ne-
phrotic range proteinuria were tested at the time of presentation
of renal disease consistent with HIV nephropathy. Thirty-one
of the ESRD patients, or 7.9%, were HIV infected as docu-
mented by ELISA and/or Western blot test. The majority of the
HIV infected patients in our population were homosexual, and
had biopsy proven HI VAN as the cause of their ESRD. A total
of 361 ESRD patients had no clinical or serological evidence of
HIV infection at the time of our final assessment (Table 1).
Survival time for each individual patient was determined by
the number of months between first and last dialysis, or death.
Survival curves were plotted based on the survival distribution
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Table 1. Characteristics of the ESRD population
N % Age years
Race and sex
Diagnosis.White
M—F
Black
M—F
. .
Hispanic
M—F DM HTN GN HI VAN 0TH UNK
All FSRD patients 392 100 147
95—52
219
129—90
26
15—Il
95 121 41 20 81 34
HIV infected patients 31 7.9 37.5 9.7 6
5—1
25
23—2
0
0—0
2 2 20 4 3
TreatedwithHD 23 5,9 34.8±7.5 5
4—1
18
16—2
0
0—0
2 1 17 2 1
TreatedwithCAPD 8 2.0 45.2 11.7 1
1—0
7
7—0
0
0—0
0 1 3 2 2
Non-HIV infected 361 92.1 49.8 15.7 141
90—51
194
106—88
26
15—11
93 119 41 0 77 31
Treated with HD 262 66.8 51.6 15.1 102
58—44
141
75—66
19
11—8
75 87 28 0 53 21
Treated with CAPD 99 25.3 45.2 16.5 39
22—17
53
3 1—22
7
4—3
18 22 13 0 24 10
Abbreviations are: M, male; F, female; DM, diabetes mellitus; HTN, hypertension; ON, glornerulonephritis; HIVAN, HIV associated
nephropathy/glomerulonephritis; 0TH, other associated kidney disease; and UKN, unknown and/or unspecified renal disease.
Data are mean sD.
function, which estimates the probability of surviving beyond
any given time point since first dialysis. These estimates were
calculated by the product-limit (Kaplan-Meier) method using
the SAS version 6.04 Procedure Lifetest [17]. Differences
between these survival curves were tested using the log-rank
test [18].
Cox proportional hazards regression was used first to predict
survival among all ESRD patients. Covariates were age at time
of entry into the ESRD program, sex, race, and HIV status. A
second Cox regression was done on HIV-infected patients only.
This included the same covariates plus stage of HIV infection.
Stage of infection was categorized according to definitions
established by the Centers for Disease Control [19].
Peritonitis rate in episodes/month at risk was calculated as a
gross mean for all CAPD patients, and the individual rates were
separately calculated for each patient with peritonitis. The
chi-square and unpaired t-tests were used to compare peritoni-
tis rates and other parameters in the two treatment groups. Data
are expressed as mean SD. Results were considered signifi-
cant if P < 0.05.
Results
Of the 392 patients studied, 31 or 7.9% were HIV infected
(Fig. 1). All these patients had HIV infection at stage III or IV
at the time of initiation of dialysis. One hundred and seven of
the 392 patients, or 27.3%, were treated with CAPD. Eight of
the 31 HIV infected patients, or 25.8%, elected to start CAPD,
while 23 HIV infected patients were treated exclusively with
HD. A total of 7.5% of the population of patients treated with
CAPD and 8.1% of the total population of patients treated with
HD were HIV infected. Two of the eight patients treated with
CAPD (25%) and five of the 23 patients treated with HD (21.7%)
had stage III disease. There was no difference between the
proportion of patients with different stages of HIV infection
treated with different modalities of ESRD therapy. The demo-
graphics of the patient population are outlined in Table 1.
There was no difference between the proportion of HIV
infected and uninfected patients treated with HD and CAPD.
HIV-infected ESRD patients were younger (37.5 9.7) than
non-HIV infected (49.8 15.7 years) patients (P < 0.0001).
Survival of the entire ESRD population is illustrated in Figure
2. Mean survival time for our entire non-HIV infected HD
population (N = 361) was 44.0 33.9 months (Fig. 2, Table 2),
while mean survival time for all 31 HIV infected patients with
ESRD was 15.5 9.9 months (P < 0.0001; Table 2, Fig. 2).
Median survival for the non-infected ESRD population was 38
months, while median survival for the 31 HIV-infected patients
was 13 months. As expected, the mortality rate for the HIV
infected patients was much higher than for the non-infected
patients (Table 3), regardless of treatment modality. Among the
non-HIV infected patients, the mortality rates for those treated
by HD and CAPD were nearly identical at 222 and 227 deaths
per 1000 person years. Among the HIV-infected ESRD pa-
tients, the mortality rates were slightly numerically lower for
CAPD patients than for HD patients (588 vs. 712 per 1000
person years, respectively), but they were not significantly
different as assessed by the log rank test. The full survival
distributions for the four groups when treatment modality and
HIV status are considered together are shown in Figure 2.
A Cox regression applied to the entire sample, controlling for
age, sex, and race, confirmed the higher mortality among the 31
HIV infected patients. The equation showed lilY infected
patients to have a high mortality compared to non-HIV infected
patients (risk ratio = 6.2; 4.0 to 9.695% C.I.; chi-square 67.1,
P C 0.0001) with age being the only other significant covariate
(chi-square = 9.6,P = 0.002). With four covariates (HIV status,
age, sex and race), HIV status was a significant predictor
(chi-square = 67.1, P C 0.0001) along with age (chi-square =
9.6, P C 0.002).
When HIV infected patients were analyzed separately, there
was no difference in mean entry age (34.8 7.5 vs. 45.2 11.7
years) or mean survival time (14.7 9.7 vs. 17.9 10.7 months,
respectively) between patients treated with HD and CAPD
(Tables 1 and 2, Fig. 2). Median survival for HIV-infected
ESRD patients treated with CAPD was 18.5 months, compared
with 13 months for those patients treated exclusively with HD.
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Fig. 2. Survival analysis of HIV infected and uninfected patients
treated with hemodialysis and CAPD. The solid thin black line indicates
survival of HIV infected patients treated with CAPD. The thin dashed
line indicates survival of HIV infected patients treated with hemodial-
ysis. The heavy large dashed line represents survival of uninfected
patients treated with CAPD, while the heavy small dashed lines
indicates survival of uninfected patients treated with hemodialysis.
HIV infected ESRD patients treated with HD, however, had
higher mean serum albumin concentration at the time of their
first dialysis treatment compared to the CAPD patients (3.6
0.8 vs. 2.7 0.9 g/dl, P <0.02).
The difference in mortality of patients treated with HD and
CAPD was tested separately for HI V-infected and non-infected
patients. Cox regression was employed, with treatment modal-
ity, age, sex, race and stage of HIV infection used as covari-
ates. Treatment modality was not a significant predictor for
either the HIV-infected (chi-square = 0.4) or non-infected
(chi-square = 0.2) patients.
Peritonitis was the most common treatment related compli-
cation, encountered in 100% of HIV-infected patients with
HD and CAPD
HIV Infected/CAPD
HIV Infected/HD
ESRD treated with CAPD. In the group of HIV-infected
patients treated with HD, arterio-venous access dysfunction
was the most common treatment related complication, involv-
ing 30.4% of patients. Pneumocystiscarinii pneumonia was the
most common non-treatment related infectious complication,
affecting 39.1% of patients treated with HD and 62.5% of
patients treated with CAPD. 17.4% of the HI V-infected patients
treated with HD and 25% of those treated with CAPD suffered
from dementia during the course of ESRD therapy. There was
no difference between the proportion of patients with dementia
in the two treatment groups. HIV infected HD patients were
hospitalized 2.6 1.2 times during the course of therapy, while
patients treated with CAPD were hospitalized 3.3 1.0 times.
There was no difference in mean number of hospitalizations
between the two treatment groups.
There were 17 episodes of peritonitis in the eight HIV-
infected patients treated with CAPD during the study period
(Table 4). Of note, six of these episodes were staphylococcal
infections. There was only one episode of an opportunistic
agent causing peritonitis. The proportion of patients with peri-
tonitis in the HIV infected population treated with CAPD was
not different from that in the uninfected population treated with
CAPD. Peritonitis rate in episodes/month at risk was not
different in HIV infected patients treated with CAPD (0.20
0.13) compared to non-HIV infected patients treated with
CAPD (0.14 0.12; Table 5). Patients with serum albumin
levels below 3 g/dl had peritonitis as frequently as those with
serum albumin levels greater than or equal to 3 g/dl.
Discussion
Our study has shown that although survival time in HIV
infected patients with ESRD was significantly diminished com-
pared to non-HIV infected dialysis patients, survival time was
not different between HIV infected patients with ESRD treated
with HD or CAPD. Age, presence of HIV infection, and the
stage of HIV infection were predictors of survival in our ESRD
patients, while sex and race were not. These data are consistent
Non-HIV Infected/CAPD
Non-HIV
Fig. 1. Distribution of HI V infected ESRD patients in hemodialysis and CAPD programs.
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Table 2. Survival in ESRD patients with and without HIV infection 1984—1992
N
Number
censored
(alive) Median
Survival on
dialysis
months P value Compared to
HIV infected patients 8 1 18.5 17.9 10,7 NS HIV infected patients
treated with CAPD treated with HD
HIV infected patients 23 3 13.0 14.7 9.7 0.0001 Non-flY infected patients
treated with HD treated with HD
LIlY infected patients with 31 4 13.0 15.5 9.9 0.0001 Non-HIV infected patients
ESRD with ESRD
Non-HIV infected patients 99 21 33.0 41.6 34.2 0.006 HIV infected patients
treated with CAPD treated with CAPD
Non-HIV infected patients 262 44 39.0 44.9 33.5 NS Non-HIY infected patients
treated with LID treated with CAPD
Non-HIV infected patients 361 65 38.0 44.0 33.9 0.0001 HIV infected patients with
with ESRD ESRD
Data are mean SD.
Table 3. Mortality rates by HIV status and treatment
Non-HIV
HD
infected
CAPD
HIV i
HD
nfected
CAPD
Deaths 218 78 20 7
Person years 979.4 343.0 28.1 11.9
Mortality rate 222 227 712 588
per 1000 person years
with reported U.S. Renal Data Systems (USRDS) statistics and
previous studies of survival of HIV infected patients treated
with HD [20—251. One year age, race and sex adjusted patient
survival for all incident dialysis patients in the 1986—1988 cohort
showed no difference for non-diabetic subjects treated with HD
or CAPD [20]. Survival in subjects analyzed by the USRDS did
vary in subsets of patknts according to age and race, but the
small number of patients in our HIV-infected population treated
with CAPD precluded such analysis. Similar findings were
reported by Burton and Walls in the United Kingdom [21],
Majorca et al in Italy [22], and Wolfe et al in the United States
[23]. Notably, there were no significant differences, however, in
mean age or the distribution of patients with regard to racial
background or renal or cormorbid disease between HIV-in-
fected CAPD or HD treated patient groups in our study popula-
tion. Rao, Friedman and Nicastri showed survival of ESRD
patients with AIDS treated with HD was poor [4]. Ortiz et al [241
and Feinfeld et al [25], however, have shown that survival in HIV
infected patients with ESRD probably depends on stage of HIV
infection. Such findings were corroborated by Reiser, Shapiro and
Porush [5] and are in agreement with our data.
Circulating albumin levels have also been shown to be an
important determinant of survival in patients treated with HD
[26]. Albumin levels have also been shown to be related to
survival in patients with ESRD treated with CAPD [27]. A
recent study suggests decreased levels of serum albumin con-
centration may be associated with increased morbidity in pa-
tients treated with CAPD [28]. It is possible that albumin loss
during CAPD might have negatively impacted upon survival in
patients treated with peritoneal dialysis. This might have been
an important consideration in HIV infected patients treated
with peritoneal dialysis, since nutrition may be an important
Table 4. Etiology of peritonitis, HIV infected patients with ESRD
treated with CAPD
Microorganism
No. of
episodes
No. of
patients
Staphylococcus epidermidis 4 3
Staphylococcus aureus 2 2
Enterococcus fecalis 2 1
Enterobucter aerogenes 2 I
a streptococcus 2 1
Pseudomonas aeruginosa 1 1
Escherichia coli 1 1
Proteus mirabilis 1 1
Serratia marcescens 1 1
Mycobacterium avium intracellulare 1 1
factor in the survival of HIV infected patients [29]. However,
HIV infected CAPD patients in our study had survival which
was not significantly different from that of patients treated with
HD, in spite of their lower mean serum albumin level at the time
of initiation of CAPD treatment and the protein losses imposed
by the treatment. This is especially important in light of the fact
that comorbid factors were similar in both groups of HIV infected
patients treated with different renal replacement therapies.
In general, HIV-infected ESRD patients had dialysis related
complications similar to those encountered in non-infected
patients. There was no difference in number of hospitalizations,
or prevalence of dementia in the two groups of HIV-infected
patients treated for ESRD.
Recently, case reports have appeared regarding opportunistic
or unusual peritoneal infections in HIV infected patients treated
with CAPD [10, 11, 13, 14]. The peritonitis rate was similar in
HIV infected and uninfected ESRD patients in our population.
In addition, the proportion of patients with peritonitis in the
HIV infected population treated with CAPD was not different
from that of the HIV negative population treated with CAPD.
The overwhelming majority of etiologic factors causing perito-
nitis in our HIV infected patients treated with CAPD were
bacterial. We had only one case of a patient with a mycobac-
terial infection. Interestingly, there were no cases of fungal or
parasitic peritoneal infections in our HIV-infected CAPD pop-
ulation.
Schloth et al [16] found a higher peritonitis rate in patients
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Table 5. Peritonitis rates in ESRD patients treated with CAPD 1985—1992
N
Peritonitis
ratea
Peritonitis rateb
Mean SD P value Compared to
All patients 107 0.12
Non-HIV infected patients 99 0.12 0.14 0.12 0.37 HIV infected patients
HIV infected patients 8 0.17 0.20 0.13 0.37 Non-HIV infected patients
a episodes per month entire populationb patients with peritonitis
with HIV infection compared to uninfected ESRD patients
treated with CAPD. In contrast, however, Wasser et a! [15] in
a preliminary report also found no difference in the prevalence
of peritonitis in HIV infected patients treated with CAPD. The
reason for these discrepancies is unknown, but may depend on
technical differences, or differences in nutrition or risk factors
for HIV infection in the populations.
The potential benefits to staff and patients of providing an
equally effective form of renal replacement therapy without
frequent venipuncture and blood loss are clear [30—35]. Al-
though nosocomial infection in dialysis units has been rare [7,
36], CAPD treatment potentially could decrease the risk of
occupational exposure to virus because of the lower frequency
of venipuncture in this population. The infectivity of peritoneal
dialysate has not been investigated, but is an important area for
study. A recent study, however, demonstrated the presence of
replication-competent HIV in peritoneal dialysis effluents in
two of three HIV infected patients with ESRD treated with
CAPD, suggesting another possible route of viral transmission
[37]. Care should be taken in the disposal of spent dialysate in
HIV infected patients treated with CAPD [371.
In summary, our data suggest that CAPD is an equally good
treatment alternative, when compared to HD treatment for HIV
infected patients with ESRD. Our studies support the recom-
mendations of the Centers for Disease Control regarding the
dialytic treatment of HIV infected patients with ESRD [2, 38].
Our results may be most applicable to a group of HIV infected
patients with a low prevalence of intravenous drug users [39].
Further studies in larger populations of patients with different
risk factors may lead to a better understanding of the indica-
tions for CAPD as a renal replacement therapy for HIV infected
patients with ESRD.
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